Resveratrol restores the level of key inflammatory cytokines and RANKL/OPG ratio in the femur of rat osteoporosis model

References

• Akinwumi, B. C., Bordun, K. M., & Anderson, H. (2018). Biological Activities of Stilbenoids. International Journal of Molecular Sciences, 19(3). doi:10.3390/ijms19030792
   PubMed Web of Science ®Google Scholar
• Corrado, A., Neve, A., Ynoue, L. H., Miranda, J. S., Pajuaba, A. C. A. M., Cunha-Júnior, J. P., … Taketomi, E. A. (2013). Bone effects of biologic drugs in rheumatoid arthritis. Clinical & Developmental Immunology, 2013, 945945. doi:10.1155/2013/657424
   PubMedGoogle Scholar
• D’Amelio, P., Grimaldi, A., Di Bella, S., Brianza, S. Z. M., Cristofaro, M. A., Tamone, C., … Isaia, G. (2008). Estrogen deficiency increases osteoclastogenesis up-regulating T cells activity: A key mechanism in osteoporosis. Bone, 43(1), 92–100. doi:10.1016/j.bone.2008.02.017
   PubMed Web of Science ®Google Scholar
• de Villiers, T. J., Chines, A. A., Palacios, S., Lips, P., Sawicki, A. Z., Levine, A. B., … Brown, J. P. (2011). Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: Results of a 5-year, randomized, placebo-controlled phase 3 trial. Osteoporosis International : a Journal Established as Result of Cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 22(2), 567–576. doi:10.1007/s00198-010-1302-6
   PubMed Web of Science ®Google Scholar
• Feng, J., Liu, S., Ma, S., Zhao, J., Zhang, W., Qi, W., … Lei, W. (2014). Protective effects of resveratrol on postmenopausal osteoporosis: Regulation of SIRT1-NF-kappaB signaling pathway. Acta biochimica et biophysica Sinica, 46(12), 1024–1033. doi:10.1093/abbs/gmu103
   PubMed Web of Science ®Google Scholar
• Gaffen, S. L., Jain, R., Garg, A. V., & Cua, D. J. (2014). The IL-23-IL-17 immune axis: From mechanisms to therapeutic testing. Nature Reviews. Immunology, 14(9), 585–600. doi:10.1038/nri3707
   PubMed Web of Science ®Google Scholar
• Gillespie, M. T., Kho, A., Krastins, B., Sarracino, D. A., Thornhill, T. S., Chase, M., … Lee, D. M. (2007). Impact of cytokines and T lymphocytes upon osteoclast differentiation and function. Arthritis Research & Therapy, 9(2), 103. doi:10.1186/ar2172
   PubMed Web of Science ®Google Scholar
• Ginaldi, L., De Martinis, M., Ciccarelli, F., Saitta, S., Imbesi, S., Mannucci, C., & Gangemi, S. (2015). Increased levels of interleukin 31 (IL-31) in osteoporosis. BMC Immunology, 16, 60. doi:10.1186/s12865-015-0125-9
   PubMed Web of Science ®Google Scholar
• Glantschnig, H., Fisher, J. E., Wesolowski, G., Rodan, G. A., & Reszka, A. A. (2003). M-CSF, TNFalpha and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase. Cell Death and Differentiation, 10(10), 1165–1177. doi:10.1038/sj.cdd.4401285
   PubMed Web of Science ®Google Scholar
• Iwakura, Y., & Ishigame, H. (2006). The IL-23/IL-17 axis in inflammation. The Journal of Clinical Investigation, 116(5), 1218–1222. doi:10.1172/JCI28508
   PubMed Web of Science ®Google Scholar
• Kharode, Y. P., Sharp, M. C., & Bodine, P. V. N. (2008). Utility of the ovariectomized rat as a model for human osteoporosis in drug discovery. Methods in Molecular Biology (Clifton, N.J.), 455, 111–124. doi:10.1007/978-1-59745-104-8_8
   PubMedGoogle Scholar
• Khosla, S. (2001). Minireview: The OPG/RANKL/RANK system. Endocrinology, 142(12), 5050–5055. doi:10.1210/endo.142.12.8536
   PubMed Web of Science ®Google Scholar
• Kong, Y. Y., Boyle, W. J., & Penninger, J. M. (2000). Osteoprotegerin ligand: A regulator of immune responses and bone physiology. Immunology Today, 21(10), 495–502.
   PubMedGoogle Scholar
• Kulkarni, S. S., & Canto, C. (2015). The molecular targets of resveratrol. Biochimica et biophysica acta, 1852(6), 1114–1123. doi:10.1016/j.bbadis.2014.10.005
   PubMed Web of Science ®Google Scholar
• Li, B., & Yu, S. (2003). Genistein prevents bone resorption diseases by inhibiting bone resorption and stimulating bone formation. Biological & Pharmaceutical Bulletin, 26(6), 780–786.
   PubMed Web of Science ®Google Scholar
• Liu, Z. P., Li, W. X., Yu, B., Huang, J., Sun, J., Huo, J. S., & Liu, C. X. (2005). Effects of trans-resveratrol from Polygonum cuspidatum on bone loss using the ovariectomized rat model. Journal of Medicinal Food, 8(1), 14–29. doi:10.1089/jmf.2005.8.14
   PubMed Web of Science ®Google Scholar
• Mori, G., D’Amelio, P., Faccio, R., & Brunetti, G. (2015). Bone-immune cell crosstalk: Bone diseases. Journal Immunology Researcher, 2015, 108451. doi:10.1155/2015/108451
   PubMedGoogle Scholar
• Ornstrup, M. J., Harslof, T., Kjær, T. N., Langdahl, B. L., & Pedersen, S. B. (2014). Resveratrol increases bone mineral density and bone alkaline phosphatase in obese men: A randomized placebo-controlled trial. The Journal of Clinical Endocrinology and Metabolism, 99(12), 4720–4729. doi:10.1210/jc.2014-2799
   PubMed Web of Science ®Google Scholar
• Redlich, K., & Smolen, J. S. (2012). Inflammatory bone loss: Pathogenesis and therapeutic intervention. Nature Reviews. Drug Discovery, 11(3), 234–250. doi:10.1038/nrd3669
   PubMed Web of Science ®Google Scholar
• Reginster, J. Y., Neuprez, A., Beaudart, C., Lecart, M. P., Sarlet, N., Bernard, D., … Bruyere, O. (2014). Antiresorptive drugs beyond bisphosphonates and selective oestrogen receptor modulators for the management of postmenopausal osteoporosis. Drugs Aging, 31(6), 413–424. doi:10.1007/s40266-014-0179-z
   PubMed Web of Science ®Google Scholar
• Sato, K., Suematsu, A., Okamoto, K., Yamaguchi, A., Morishita, Y., Kadono, Y., … Takayanagi, H. (2006). Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. The Journal of Experimental Medicine, 203(12), 2673–2682. doi:10.1084/jem.20061775
   PubMed Web of Science ®Google Scholar
• Singh, S. U., Casper, R. F., Fritz, P. C., Sukhu, B., Ganss, B., Girard, B., … Tenenbaum, H. C. (2000). Inhibition of dioxin effects on bone formation in vitro by a newly described aryl hydrocarbon receptor antagonist, resveratrol. The Journal of Endocrinology, 167(1), 183–195.
   PubMed Web of Science ®Google Scholar
• Suresh, E., Pazianas, M., & Abrahamsen, B. (2014). Safety issues with bisphosphonate therapy for osteoporosis. Rheumatology (Oxford, England), 53(1), 19–31. doi:10.1093/rheumatology/ket236
   PubMed Web of Science ®Google Scholar
• Talaat, R. M., Sidek, A., Mosalem, A., & Kholief, A. (2015). Effect of bisphosphonates treatment on cytokine imbalance between TH17 and Treg in osteoporosis. Inflammopharmacology, 23(2–3), 119–125. doi:10.1007/s10787-015-0233-4
   PubMed Web of Science ®Google Scholar
• Teitelbaum, S. L. (2007). Osteoclasts: What do they do and how do they do it? The American Journal of Pathology, 170(2), 427–435. doi:10.2353/ajpath.2007.060834
   PubMed Web of Science ®Google Scholar
• Tou, J. C. (2015). Resveratrol supplementation affects bone acquisition and osteoporosis: Pre-clinical evidence toward translational diet therapy. Biochimica et biophysica acta, 1852(6), 1186–1194. doi:10.1016/j.bbadis.2014.10.003
   PubMed Web of Science ®Google Scholar
• Tresguerres, I. F., Tamimi, F., Eimar, H., Barralet, J., Torres, J., Blanco, L., & Tresguerres, J. A. F. (2014). Resveratrol as anti-aging therapy for age-related bone loss. Rejuvenation Research, 17(5), 439–445. doi:10.1089/rej.2014.1551
   PubMed Web of Science ®Google Scholar
• Wang, H.-D., Shi, Y.-M., Li, L., Guo, J.-D., Zhang, Y.-P., & Hou, S.-X. (2013). Treatment with resveratrol attenuates sublesional bone loss in spinal cord-injured rats. British Journal of Pharmacology, 170(4), 796–806. doi:10.1111/bph.12301
   PubMed Web of Science ®Google Scholar
• Xuzhu, G., Komai-Koma, M., Leung, B. P., Howe, H. S., McSharry, C., McInnes, I. B., & Xu, D. (2012). Resveratrol modulates murine collagen-induced arthritis by inhibiting Th17 and B-cell function. Annals of the Rheumatic Diseases, 71(1), 129–135. doi:10.1136/ard.2011.149831
   PubMed Web of Science ®Google Scholar
• Yago, T., Nanke, Y., Ichikawa, N., Kobashigawa, T., Mogi, M., Kamatani, N., & Kotake, S. (2009). IL-17 induces osteoclastogenesis from human monocytes alone in the absence of osteoblasts, which is potently inhibited by anti-TNF-alpha antibody: A novel mechanism of osteoclastogenesis by IL-17. Journal of Cellular Biochemistry, 108(4), 947–955. doi:10.1002/jcb.22326
   PubMed Web of Science ®Google Scholar
• Zhang, J., Fu, Q., Ren, Z., Wang, Y., Wang, C., Shen, T., … Wu, L. (2015). Changes of serum cytokines-related Th1/Th2/Th17 concentration in patients with postmenopausal osteoporosis. Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology, 31(3), 183–190. doi:10.3109/09513590.2014.975683
   PubMed Web of Science ®Google Scholar
• Zhang, L., Wen, X., Li, M., Li, S., & Zhao, H. (2018). Targeting cancer stem cells and signaling pathways by resveratrol and pterostilbene. BioFactors (Oxford, England), 44(1), 61–68. doi:10.1002/biof.1398
   PubMed Web of Science ®Google Scholar
• Zhao, L., Wang, Y., Wang, Z., Xu, Z., Zhang, Q., & Yin, M. (2015). Effects of dietary resveratrol on excess-iron-induced bone loss via antioxidative character. The Journal of Nutritional Biochemistry, 26(11), 1174–1182. doi:10.1016/j.jnutbio.2015.05.009
   PubMed Web of Science ®Google Scholar